Table 3. Infectivity of midgut sporozoites for the vertebrate host.
| Parasite | Sporozoites injected | Mice infected | Pre-patent perioda |
| Pbwt | 100,000 | 0/3 | - |
| 300,000 | 2/4 | 7.0 | |
| 500,000 | 1/2 | 6.0 | |
| PbCSDHFR cl9 | 500,000 | 1/4 | 8.0 |
| PbCSDHFR cl10 | 500,000 | 1/2 | 7.0 |
| PgCSSX cl1 | 500,000 | 0/5 | - |
| PgCS/PbRR cl4 | 500,000 | 0/4 | - |
| PgCS/PbRR cl5 | 500,000 | 0/4 | - |
| PbCS/PgCT cl3 | 500,000 | 1/5 | 8.0 |
| PbCS/PgCT cl6 | 500,000 | 2/5 | 7.0 |
a
Pre-patent period is the number of days between injection and first appearance of the parasites in the peripheral blood.
C57BL/6 mice were injected intravenously with Pbwt or transgenic midgut sporozoites collected on day 21 p.i.. The number of mice that became infected and the pre-patent period were both recorded.